# PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

> **NCT03740893** · PHASE2 · RECRUITING · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 119 (estimated)

## Conditions studied

- Breast Neoplasm
- Triple Negative Breast Cancer (TNBC)
- HRD

## Interventions

- **DRUG:** AZD6738
- **DRUG:** Olaparib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03740893
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-15
- **Primary completion:** 2026-12
- **Final completion:** 2029-06
- **Target enrollment:** 119 (ESTIMATED)
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03740893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03740893, "PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03740893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*